Eli Lilly’s Eloralintide has now been available on the grey market for several months and, with the drug currently in clinical trials, most people who follow grey-market peptide content have probably heard of it by now. I’ve already covered what Elora is, its unusual structure and why testing it may prove more complicated than testing many of the peptides we’re used to seeing, so I’m not going to go over all of that again. What we know far less about is the question most people actually want answered:
Is it any good?
There are user experiences out there, but compared with Reta or Tirz, there still aren’t that many detailed first hand reports showing what happens when people actually use Elora over a period of time. And even when you find one, a comment after the first injection doesn’t necessarily tell you very much.
So I decided to try and collect as many real user experiences as I could find and, wherever possible, follow the same people over time to see whether what they were saying after their first dose was still what they were saying several weeks later. The final dataset contains 76 classified accounts, including 66 confirmed first hand reports. Of those, 62 involved grey-market use and four came from people claiming completed clinical-trial exposure. A further five people were taking part in blinded trials, but because their treatment allocation couldn’t be established, I didn’t count them as confirmed Elora experiences.
In total, I retained 212 posts, comments and follow-ups. Fifty-one of the confirmed users had more than one retained event, which meant I could follow most of the more detailed experiences beyond a single first impression. That turned out to be rather important. Some people who initially felt almost nothing later reported considerable suppression. Others started off enthusiastic but eventually reduced their dose or stopped. Fatigue that looked temporary could still be causing problems weeks later. And most importantly, strong appetite suppression didn’t always translate into weight loss. I soon realised that the first post was often only just the beginning of the story.
First, what do I mean by a confirmed user?
For this research, “confirmed” means there was a sufficiently clear first-person statement establishing that the person had actually administered or used what they described as Elora. It doesn’t mean I confirmed that their vial contained Eloralintide and that caveat is crucial. None of the retained grey-market accounts has independent analytical identity testing securely tied to the exact vial that person had used. There are vendor COAs, discussions about testing, supplier disputes and allegations about incorrectly labelled products, but none gives me a clean chain from independently identified Eloralintide to the actual vial used by one of these people. So when I refer to a grey-market Elora experience, I’m describing an experience with products sold or described as Elora. A strong reaction doesn’t prove the vial contained Eloralintide, but conversely neither does a complete lack of effect prove it didn’t. That uncertainty sits behind virtually every grey-market account in this article.
Most people weren’t using Elora alone
This is probably the biggest obstacle to working out what Elora itself was doing. Most people were stacking it, either with Tirz, with Reta, with Tirz and Reta. Or they were taking Elora while lowering Tirz or after taking Cagri or alongside other peptides. Only a relatively small number appeared to have used Elora alone for a meaningful period. That makes many of the reported results impossible to attribute cleanly. If somebody adds Elora while reducing Tirz and suddenly feels better, was Elora responsible or were they simply experiencing fewer effects from Tirz? If someone adds Elora to Reta and breaks a plateau, what caused the weight loss? If someone becomes exhausted while using three different agonists, which one gets the blame? And the more complicated the stack, the less confidence we can have in assigning any result to Elora itself.
But the stacking also revealed something interesting.
Elora seems to be used as a missing piece
A lot of people weren’t necessarily trying to replace their existing drug. They were trying to fix something. Food noise had returned. Appetite control was wearing off before the next injection. They’d stalled. Reta still seemed useful but wasn’t controlling hunger as well as it once had. They wanted to reduce Tirz or Reta rather than increase it again. They disliked how Cagri felt. One user was effectively using Elora to cover the final two days before the next weekly Tirz injection and later planned to stop Elora temporarily just to see whether it was actually needed. Another reported strong suppression while taking Tirz down to zero and reducing Reta.
So Elora isn’t simply being treated as “the next weight-loss peptide.” In many of these accounts, it’s being used as an add-on for a specific problem: food noise, waning appetite control, a stall or an attempt to reduce another drug.
What doses were people using?
Reported grey-market doses commonly fell somewhere around 0.5 to 3 mg, although there were starts around 0.25 mg and later reports at 4 mg and 6 mg. Weekly dosing was common, but not universal. Some people reported every 12 days, fortnightly use or variable four-to-seven-day schedules. But plenty of posts didn’t clearly state frequency at all. These are simply reported practices, not dosing recommendations. They also make comparison between users difficult.
Someone saying 1 mg did nothing after their first injection isn’t really comparable with somebody taking 1 mg after several previous doses, somebody coming off high-dose Tirz or someone taking it every five days alongside Reta. Even when two users write the same number, the surrounding circumstances can be completely different.
At one end, some people felt almost nothing
There were genuine nonresponse stories. One user progressed from a reported 1 mg to 2 mg and then 3 mg over several weeks and repeatedly said they felt nothing. Eventually, the lack of response led them to question the product itself.
Another user is particularly interesting because they described a period of apparent solo use. They progressed through 1 mg, then higher amounts and eventually 4 mg by week four, but still described the experience as disappointing.
At lower doses the contrast was just as striking. Some people described useful suppression around 0.5 mg, while another said they felt nothing at the same reported amount. One person still felt nothing at 3 mg while another described same-day suppression and slight nausea after a reported 3 mg dose. That variation could reflect individual biology. It could also reflect previous GLP exposure, other drugs, inaccurate dosing or differences in what was actually in the vial. Unfortunately, there’s no way to separate those explanations from these reports alone.
Sometimes nothing became something
One user initially reported that 1 mg hadn’t done very much. A later update was almost the opposite: hardly any hunger. Another started with no obvious response and later said they liked the appetite effect, but by then fatigue and constipation had appeared as well. That’s exactly why counting individual posts as individual experiences gives such a distorted picture. “Did nothing” and “I like it but it makes me tired and constipated” can belong to the same person at different points in their timeline.
The most interesting timeline went from working, to not working, to working too well
One of the longest forum histories is probably the best example of why the first post can be so misleading. The user started by describing appetite suppression during week one after reported dosing around 3 mg and increasing to 5 mg. But by week two, very little seemed to be happening. A couple of days later, an effect that had originally felt strong was described as almost gone. By around week five, Elora appeared to be providing only modest background help. If the story had ended there, it would have been easy to classify it as a promising start followed by disappointment. It didn’t and later posts described the suppression becoming considerably stronger. The user believed there had been a delayed effect, reported weight moving again after a long plateau and eventually described around 4 to 6 kg lost over roughly a month. By then, the problem had completely reversed. Eating had become difficult enough that reducing the reported dose from 5 mg back to 3 mg was being considered. But Tirz remained in use, previous Reta and Cagri exposure complicated the picture and calorie intake had changed, so this can’t be treated as a clean Elora weight-loss result.
But as a user timeline it’s fascinating. The same person effectively went through:
It works. Maybe it doesn’t. It helps a little. Now it is doing a lot. Maybe it is doing too much.
That entire story disappears if you only read the first post.
Stronger isn’t necessarily better
One of the things I noticed repeatedly is that social-media peptide coverage often treats maximum appetite suppression as a sign of success. If somebody can barely think about food, great. If they can barely eat, even better. But some of these accounts show why that’s too simplistic.
One user taking reported Elora 2 mg alongside Tirz 10 mg eventually stopped because the suppression interfered with their ability to eat enough. They also reported reduced thirst.
Another reported almost no appetite together with severe lethargy, brain fog, constipation and unusual crying.
A separate user described going around 20 hours without even noticing a need to eat.
Others experienced strong suppression and were perfectly happy with it.
These are all very different experiences hidden underneath the phrase “strong suppression.”
Comfortable satiety can become food aversion
Another user initially described food as manageable. They could eat and stop when full. Later, the story had changed. The user reported substantial weight loss while also taking Reta, but also described being unable to eat properly and having no energy. After a break, a lower reported dose seemed more tolerable, although food aversion was still present. That account had moderator/group-buy promotional involvement, so I excluded it from the conservative independent analysis rather than treating it as clean evidence. I didn’t assume the user was lying, I just didn’t want commercially connected accounts driving the overall conclusions.
Food noise, hunger, satiety and food aversion are different things
Another problem with the way Elora is discussed is that everything gets bundled under the word “suppression.” But these are different experiences. A person can still experience physical hunger while thinking about food far less. Someone can feel full sooner while still enjoying a meal. Someone can stop caring about food. Someone can feel actively put off by it. And somebody else may simply forget to eat.
Several users described Elora as giving them satiety without the unpleasant food aversion they associated with Cagri. Others went much further and described struggling to eat.
The clearest pattern across the dataset was therefore not one particular response, but a spectrum: from nothing, through useful food-noise control and persistent fullness, all the way to suppression that interfered with eating.
Appetite suppression and weight loss are not the same thing
This became one of the most useful findings in the whole exercise. One user reported clear food-noise benefit but no weight impact. Another had considerable suppression and unpleasant side effects but eventually reported no weight loss during that period. A longer-term forum user still valued the satiety even though there had been no weight loss over the previous three weeks. That matters because social media tends to treat these statements as interchangeable: I can barely eat. My food noise has gone. This stuff is powerful. It works. Those statements tell us something about appetite, but they don’t tell us how much weight somebody has lost.
People did report weight loss
There are still plenty of reported numbers. In the grey-market accounts, I found people reporting 1 lb after a longstanding stall, 3 lb over roughly three weeks, around 6 lb after a plateau and 2 lb during the second week. There were also much larger figures. But the problem is that nearly all of the more impressive numbers were surrounded by other variables.
One person increased Tirz during the same period. Another was using Reta. Others had high and changing exposure to several drugs. Forum users reported losses while combining Elora with Reta and semaglutide, Elora with tesamorelin/ipamorelin after recent Tirz, or Elora while continuing Tirz after previous Reta/Cagri use. So yes, people report weight loss after adding Elora, but these accounts can’t tell us how much weight Elora itself causes people to lose.
Some of the stacks are almost impossible to untangle
One recovered regimen is a good illustration. The user reported Tirzepatide 15 mg and Retatrutide 2 mg every five days, followed two days later by Elora 0.8 mg. So if hunger improves, which drug did it? If fatigue develops, which one caused it? If the scales move, what gets the credit?
This may not be useful for determining Elora’s independent effects, but it’s useful for understanding how some grey-market users are approaching these compounds. They’re not necessarily treating them as individual drugs. They’re building stacks and adjusting components depending on hunger, side effects, stalls and personal preference.
Fatigue is the negative theme that keeps coming back
If there’s one adverse experience that repeatedly appears across the longer histories, it’s fatigue. The descriptions ranged from feeling sluggish to afternoon crashes, sleeping much of the next day, brain fog and substantial lethargy. Some reported it even at relatively low doses. Some lowered the dose. Some took breaks. Others questioned whether the appetite benefit was worth the tiredness.
But fatigue was certainly not universal.
Several users specifically reported no fatigue at the point they were assessed, so I’m not saying Elora “causes fatigue”. What I can say is that fatigue was one of the most persistent recurring negative experiences in these reports, and for some people it was significant enough to affect whether or how they continued using the product.
Early improvement in fatigue did not always last
One longer forum account initially suggested tiredness was getting better after the second dose. But by week ten, it was still significant enough to affect dosing. The user had reduced from 1 mg to 0.8 mg and still described needing naps, although they continued to value the satiety and improved sleep. That account also involved Reta and Tirz, so there is no clean way of assigning the fatigue to Elora. But it demonstrates why an early comment saying “the fatigue seems to be easing” isn’t necessarily the end of the story.
Is it less fatiguing than Cagri?
Some people clearly thought so. Several users who’d tried both described Elora as giving them comparable appetite control with less nausea, less food aversion or less fatigue. One described Cagri-like persistent fullness without the same episodes of substantial mental fatigue. Another later reported fatigue on Elora but still considered it milder than their Cagri experience.
But there was also at least one user who said the exact opposite and found Elora fatigue worse. So there’s no defensible basis for saying Elora is simply better tolerated than Cagri. What the reports suggest is that some people prefer the type of appetite control or side-effect profile they experience with Elora, while others don’t.
The Cagri comparison became more complicated with follow-up
One of the better comparative histories involved a user who gradually increased Elora while simultaneously reducing Tirz. They described strong persistent fullness and little interest in food, broadly similar to Cagri, but initially without the same degree of mental fatigue. Later they reported better sleep, improved mood and somewhat greater productivity. That sounds very favourable until you remember that Tirz was being reduced at the same time. The user themselves acknowledged that and suggested the lower Tirz could be responsible for at least some of the improvement. Later still, considerable gas appeared.
A single sentence saying “Elora feels better than Cagri” would miss nearly everything useful about the experience.
Constipation is the most repeated GI complaint, but it isn’t the only one
Constipation appeared repeatedly. There were also reports of nausea, reflux, loose stools, diarrhoea, gas and sulphur burps. Some symptoms appeared almost immediately, while others emerged weeks later. And in many cases another drug, travel or dietary changes were occurring at the same time.
One particularly useful timeline started with two days of constipation that then resolved. Later came diarrhoea, a week of sulphur burps and significant gas. Meanwhile, appetite suppression had continued to increase, eventually contributing to a plan to reduce the dose and stop. Again, the week-one experience and the week-five experience looked very different.
Injection-site reporting tells us very little
Only a small number of users said anything about injection-site effects. One explicitly reported no burn or reaction, but most simply never mentioned it. That means I can’t take silence and turn it into “no injection-site reaction”.
The same applies to every other side effect. If a user didn’t mention nausea, that is not stated, not “no nausea”. That’s one reason this dataset should never be turned into clinical incidence percentages.
Sleep reports went in every direction
Some people said they slept better, others reported sleep disturbance. One described vivid dreams. One wondered whether improved sleep was simply because the fatigue made them more tired. Another thought reducing Tirz might explain the improvement. A user with insomnia simply continued having insomnia.
There’s no clean sleep story here. The only sensible conclusion is that sleep experiences were mixed.
Mood was equally mixed
There were reports of emotional fluctuations, unusual crying and low motivation. One user described good food-noise control but found the emotional effects difficult. Another described crying, lack of motivation and brain fog alongside severe lethargy and constipation. At the other end, there were users reporting improved mood or a calmer mind. But those accounts were often confounded by reductions in Tirz or by the fact that “calmer mind” referred specifically to thoughts about food.
That distinction matters. Reduced food noise isn’t necessarily improved mood. And losing interest in food isn’t the same thing as losing interest in everything.
The anhedonia question
Several people specifically compared Elora with previous experiences of anhedonia on other drugs. One reported having experienced anhedonia on Tirz and Cagri but not while using Elora. Another said their Elora period felt less anhedonic than Reta. That’s interesting, but it’s not evidence that Elora treats anhedonia. The first user was also taking Reta and semaglutide. Another user who reported better mood and productivity was simultaneously reducing Tirz.
There are too many moving pieces to isolate Elora as the cause. The most cautious conclusion is simply that some individuals perceived the mental experience as different from other agonists they had used.
Elora with Reta
Reta appeared again and again. Some users added Elora because Reta’s appetite effect seemed to be fading. Some had stalled. Some disliked other Reta effects. Others wanted to reduce Reta without losing appetite control. Some said the combination restored suppression. Others felt almost nothing.
But once somebody lowers Reta and adds Elora at the same time, a lot can change: heart rate, hunger, mood, sleep and energy. If those things improve, Elora can’t automatically get the credit. If they get worse, it can’t automatically get the blame either.
One of the more interesting apparent solo periods
One user moved from Reta overlap into a period where they reported using Elora alone. They started around 1.5 mg, progressed to 2 mg and eventually 6 mg after suppression seemed to weaken. They remained broadly positive about the product. Fatigue persisted, but sleep was described more positively.
That apparent solo period is more useful than many of the stack reports, but it’s still not a clean experiment. The person had previous Reta exposure and was changing the Elora dose considerably.
Elora with Tirz
With Tirz, Elora often seemed to be used to fill a gap rather than replace it. Some users wanted more control of food noise. Some wanted extra coverage later in the week. Some hoped to lower Tirz. One forum user was essentially using Elora for the final two days before the next weekly Tirz dose. Other users said Elora allowed them to delay or reduce Tirz.
But that makes it difficult to know what caused any improvement. If somebody feels better while Tirz is reduced and Elora is added, it may be Elora. It may be the reduction in Tirz, or it may be both.
The commercially connected accounts did not create the overall pattern
Six of the grey-market accounts had moderator, organiser, resale or promotional links. Rather than assuming those people were lying, I kept their reports in the main evidence but removed them from a more conservative analysis. The same broad findings survived. There were still non responders, there was still severe suppression. Fatigue remained and constipation and other GI symptoms remained. Food-noise benefit without current weight loss remained. The Cagri comparison remained mixed.
So the main themes weren’t being created entirely by the commercially connected accounts.
The claimed clinical-trial experiences need their own category
The final dataset also contains four people claiming completed clinical-trial exposure. These accounts are fundamentally different from somebody buying a grey-market vial. Their reported histories are compatible or partly compatible with a 48-week Phase 2 study that included placebo, a fixed 9 mg arm and dose-escalation groups. But compatibility doesn’t prove allocation. Without documentation showing which treatment arm somebody actually received, I can’t convert a self-reported trial history into independently verified eloralintide exposure. So that’s why I’ve kept these users separate from the 62 grey-market lab rats.
The most striking trial report
One retrospective account described what the user believed had been 9 mg exposure. They reported nearly 90 lb lost, prolonged appetite suppression during the study and food noise returning after the trial ended. Later came intermittent Zepbound use. The same longer timeline also included hair loss and subsequent gallstone surgery. All of those details are relevant to the person’s story, but none of them should automatically be attributed to Elora. The report doesn’t establish that Elora caused the weight loss, or the hair loss, or the gallstones or the later surgery.
They occurred in the person’s timeline and that’s all the evidence allows me to say.
Two trial histories looked remarkably similar
One account from one community and another from elsewhere both described roughly 48 weeks, a reported 9 mg dose and weight-loss histories in a similar range. That’s enough to make me wonder whether they could be the same person, but it’s not enough to merge them. There was no direct evidence linking the identities, so they remain separate in the dataset. That may sound like a small detail, but with only 66 confirmed users, incorrectly counting the same person twice, or wrongly merging two different people, actually makes a difference.
The five blinded participants were not counted as Elora users
Another five people were discussing experiences while taking part in blinded trials. They were not included in the 66 confirmed reports and that’s deliberate. A person enrolled in a study containing an Elora arm doesn’t necessarily know they received Elora. They may be receiving another active treatment or they may be on placebo.
Participants often guess what they received based on appetite suppression, nausea or weight loss, but that guess isn’t proof.
So these accounts are useful mainly because they show why statements such as “someone in the Elora trial lost X pounds” can be very misleading. Until treatment allocation is actually known, it’s not an Elora experience.
And then there is the grey-market identity problem
The 62 grey-market accounts have an even more fundamental uncertainty. What was actually in the vial? The source material contains allegations of batch problems, underfill, overfill, mislabelling and even Selank substitution. One repeated non responder associated their ineffective product with a particular batch or vial type. Another person reported an acute response while discussing independent testing. But none of that allows me to declare a supplier’s Elora is a fake.
The existing evidence doesn’t independently establish the contents of all those products, and a person’s “feelz” can’t identify a peptide. So every grey-market experience contains an unanswered question: Was this the person’s response to eloralintide, or was it their response to whatever was actually in the vial?
Users introduce another layer of variability
There were also differences in storage, preparation and use. One user reported using the same reconstituted vial for around 14 weeks and adjusting the dose because they assumed it had degraded. Others discussed experimenting with diluents and pH. These are interesting grey-market practices, but they’re not evidence that degradation actually occurred, that one diluent was better or that a particular storage method was safe. But they add yet another variable when comparing one person’s experience with another.
So what survives when all the caveats are added?
Quite a lot actually.
The experiences range from no apparent effect to appetite suppression strong enough to interfere with eating.
Food noise and satiety seem to be major reasons people are interested in Elora, sometimes more than weight loss itself.
Appetite suppression and weight change don’t always move together.
Fatigue repeatedly appears and can be significant enough to affect dosing or continuation.
Constipation is the most repeated GI complaint, but nausea, reflux, diarrhoea, gas and sulphur burps also appear.
Sleep can improve or worsen.
Mood reports go in both directions.
Some people prefer Elora to Cagri because the appetite control feels less unpleasant, while at least one person found the fatigue worse.
People are using Elora to reduce or supplement Tirz and Reta.
True apparent solo use is relatively uncommon.
And the overwhelming majority of grey-market exposures remain chemically unverified.
How does any of this compare with the actual trials?
After going through all of these user experiences, the obvious question is whether any of what people are reporting bears much resemblance to what’s actually been seen in Lilly’s clinical trials. Surprisingly, quite a lot of it does.
That doesn’t mean the grey-market reports confirm the trial results. The trial participants received known study drug under controlled conditions, whereas most of the people in my dataset were using unverified grey-market material, often alongside Tirz, Reta or several other compounds. But there are some interesting similarities.
Where the trials and the user reports seem to meet
Taken together, a few themes appear on both sides:
Appetite and satiety effects; clearly present in the clinical trials and dominant in the real-world reports.
Weight loss over time; clearly demonstrated in the controlled trial, while real-world users also report losses but usually with too many confounders to attribute them to Elora.
Fatigue; one of the most noticeable adverse events at higher Phase 2 doses and also one of the strongest recurring complaints in my user dataset.
GI effects; nausea, diarrhoea and constipation appear in both.
Dose and time matter; the trial shows different tolerability depending on dose and escalation, while the real-world timelines repeatedly show experiences changing over several weeks.
But there is an equally important difference. The trial tells us what happened when people were randomised to known doses of authenticated study drug under controlled conditions. My dataset tells us what people said happened when they used Elora in the real world, mostly grey-market products, often in stacks, with self-selected doses and no confirmation of vial identity. The similarities are interesting, but they’re not proof that the two groups were experiencing exactly the same thing.
What this research does not tell us
It doesn’t tell us;
How effective pharmaceutical Eloralintide is
The average amount of weight someone will lose.
It doesn’t give us a response rate.
How common fatigue or constipation really are.
Establish that Elora is safer or better tolerated than Cagri.
Prove Elora treats anhedonia.
An optimal or safe dose.
Authenticate the contents of anybody’s grey-market vial.
What it does give us is a much more realistic picture of what people are reporting when they actually use something they believe is Elora.
The first post is not the experience
This started as an attempt to answer a simple question: Is Elora any good?
I don’t think 66 user reports give us a simple yes or no, but what they do show is how misleading the first answer can be. Social media encourages us to reduce drug experiences to one-line reviews, but the longer these users were followed, the less useful those snapshots became.
So after 66 confirmed first hand reports and 212 retained posts, comments and follow-ups, the question I find most useful is no longer: “What happened after the first dose?” It’s: “What were they saying six weeks later?” Because with Elora, the first post was very often not the experience.
Comments